X

Drug Profile

Dianicline

Alternative Names: SSR 591813

Latest Information Update: 27 Feb 2008

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator sanofi-aventis
Class Azepines; Heterocyclic compounds with 4 or more rings; Small molecules; Smoking cessation therapies
Mechanism of Action Nicotinic receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

Highest Development Phases

Discontinued CNS disorders; Smoking withdrawal

Most Recent Events

01 Oct 2007 Phase III development is ongoing
30 Mar 2006 Phase-III clinical trials in Smoking withdrawal in European Union (PO)
31 Aug 2005 Data from a media release have been added to the Drug Withdrawal therapeutic trials section

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com